Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Syed Wasi Hassan"'
Autor:
Kristina S. Boye, Dara Stein, Louis S. Matza, Jessica Jordan, Ren Yu, Kirsi Norrbacka, Syed Wasi Hassan, Luis-Emilio García-Pérez
Publikováno v:
Drugs in R&D, Vol 19, Iss 2, Pp 213-225 (2019)
Abstract Introduction Patients with type 2 diabetes mellitus (T2DM) who fail to meet glycaemic control are at increased risk of diabetes complications. For patients who cannot maintain glycaemic control with oral medication, one recommended option is
Externí odkaz:
https://doaj.org/article/99e88e125fc044d781b3c197648faf13
Autor:
Jessica B Jordan, Louis S. Matza, Kirsi Norrbacka, Kristina S. Boye, Luis-Emilio Garcia-Perez, Ren Yu, Syed Wasi Hassan, Dara Stein
Publikováno v:
Drugs in R&D
Drugs in R&D, Vol 19, Iss 2, Pp 213-225 (2019)
Drugs in R&D, Vol 19, Iss 2, Pp 213-225 (2019)
Introduction Patients with type 2 diabetes mellitus (T2DM) who fail to meet glycaemic control are at increased risk of diabetes complications. For patients who cannot maintain glycaemic control with oral medication, one recommended option is to add a
Autor:
Abigail Tebboth, Anna Scowcroft, John Bolodeoku, William Spencer, Paula Bingham-Gardiner, Syed Wasi Hassan, Sally Lee
Publikováno v:
Clinical Therapeutics. 39:1266-1270
Autor:
Jasmina I. Ivanova, Syed Wasi Hassan, Arash Tahbaz, Dachuang Cao, Iskandar Idris, Irene Hadjiyianni, Kunal Gulati, Magaly Perez-Nieves
Publikováno v:
Primary care diabetes. 13(2)
Aim Real-world effectiveness of insulin therapy is affected by poor treatment persistence, often occurring soon after initiation. An international cross-sectional survey of people with type 2 diabetes mellitus (T2DM) has been conducted to describe re
Autor:
Dachuang Cao, Irene Hadjiyianni, Michael Cummings, Liza L. Ilag, Arash Tahbaz, Meng H. Tan, Syed Wasi Hassan
Publikováno v:
Diabetes & Metabolism. 43:A79-A80
Autor:
John Bolodeoku, Paula Bingham-Gardiner, Syed Wasi Hassan, Anna Scowcroft, Abigail Tebboth, Sally Lee, William Spencer
Publikováno v:
Clinical Therapeutics. 38:1825-1832.e15
Purpose The majority of people with type 2 diabetes mellitus (T2DM) will develop chronic kidney disease in their lifetime. Because most dipeptidyl peptidase (DPP)-4 inhibitors require dose adjustment in patients with T2DM and renal impairment, we aim